A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is urgently needed to tackle the COVID-19 global pandemic. Here, we describe the development of chimpanzee adenovirus seroty...
详细信息
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is urgently needed to tackle the COVID-19 global pandemic. Here, we describe the development of chimpanzee adenovirus serotypes 6 and 68(AdC6 and AdC68) vector-based vaccine candidates expressing the full-length transmembrane spike glycoprotein. We assessed the vaccine immunogenicity, protective efficacy, and immune cell profiles using single-cell sequencing in mice. Mice were vaccinated via the intramuscular route with the two vaccine candidates using prime-only regimens or heterologous prime-boost regimens. Both vaccines elicited strong and long-term antibody and T cell responses, balanced Th1/Th2 cell responses, robust germinal centre responses, and provided effective protection to mouse lungs after SARSCoV-2 infection. Importantly, the optimal AdC68-S+AdC6-S prime-boost regimen induced the highest titres of spike-specific binding antibodies and neutralizing antibodies, and provided complete protection in mice. Potent neutralizing antibodies produced against the highly transmissible SARS-CoV-2 variants B.1.1.7 lineage(also known as N501Y.V1) and B.1.351 lineage(also known as N501Y.V2) were detectable in mouse sera over six months after prime immunization. Our Results demonstrate that the AdC68-S+AdC6-S prime-boost vaccine is a promising candidate for further development of vaccines that prevent SARS-CoV-2 infection.
暂无评论